US20060078971A1 - Isoflavone-beta-D-glucan produced by Agaricus blazei in the submerged liquid culture and method of producing same - Google Patents
Isoflavone-beta-D-glucan produced by Agaricus blazei in the submerged liquid culture and method of producing same Download PDFInfo
- Publication number
- US20060078971A1 US20060078971A1 US11/282,901 US28290105A US2006078971A1 US 20060078971 A1 US20060078971 A1 US 20060078971A1 US 28290105 A US28290105 A US 28290105A US 2006078971 A1 US2006078971 A1 US 2006078971A1
- Authority
- US
- United States
- Prior art keywords
- isoflavone
- glucan
- molecular weight
- medium
- low
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229920002498 Beta-glucan Polymers 0.000 title claims abstract description 120
- 241001327634 Agaricus blazei Species 0.000 title claims abstract description 93
- 238000009630 liquid culture Methods 0.000 title claims abstract description 54
- 238000000034 method Methods 0.000 title claims abstract description 25
- 208000035404 Autolysis Diseases 0.000 claims abstract description 78
- 206010057248 Cell death Diseases 0.000 claims abstract description 78
- 230000028043 self proteolysis Effects 0.000 claims abstract description 78
- 102000004190 Enzymes Human genes 0.000 claims abstract description 77
- 108090000790 Enzymes Proteins 0.000 claims abstract description 77
- 230000002766 immunoenhancing effect Effects 0.000 claims abstract description 15
- 239000002609 medium Substances 0.000 claims description 85
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 26
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 26
- 235000008696 isoflavones Nutrition 0.000 claims description 26
- 239000001963 growth medium Substances 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000001093 anti-cancer Effects 0.000 abstract description 21
- 229940088598 enzyme Drugs 0.000 description 74
- 210000004027 cell Anatomy 0.000 description 58
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 54
- 238000011282 treatment Methods 0.000 description 26
- 238000002835 absorbance Methods 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 238000004128 high performance liquid chromatography Methods 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- 239000000284 extract Substances 0.000 description 19
- 150000004676 glycans Chemical class 0.000 description 19
- 229920001282 polysaccharide Polymers 0.000 description 19
- 239000005017 polysaccharide Substances 0.000 description 19
- 239000002244 precipitate Substances 0.000 description 19
- 239000002158 endotoxin Substances 0.000 description 18
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 17
- 239000000463 material Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 229920006008 lipopolysaccharide Polymers 0.000 description 16
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical compound [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 15
- FYGDTMLNYKFZSV-WFYNLLPOSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3s,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-WFYNLLPOSA-N 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 14
- 231100000135 cytotoxicity Toxicity 0.000 description 14
- 230000003013 cytotoxicity Effects 0.000 description 14
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 230000037396 body weight Effects 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 238000004809 thin layer chromatography Methods 0.000 description 12
- 244000068988 Glycine max Species 0.000 description 11
- 235000010469 Glycine max Nutrition 0.000 description 11
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 235000000346 sugar Nutrition 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 10
- 235000006539 genistein Nutrition 0.000 description 10
- 229940045109 genistein Drugs 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 235000007240 daidzein Nutrition 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 240000000599 Lentinula edodes Species 0.000 description 7
- 235000001715 Lentinula edodes Nutrition 0.000 description 7
- 241000001727 Tropicoporus linteus Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 150000002338 glycosides Chemical group 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 150000008163 sugars Chemical class 0.000 description 7
- 244000234623 Coprinus comatus Species 0.000 description 6
- 235000004439 Coprinus comatus Nutrition 0.000 description 6
- 240000008397 Ganoderma lucidum Species 0.000 description 6
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 6
- 235000007685 Pleurotus columbinus Nutrition 0.000 description 6
- 240000001462 Pleurotus ostreatus Species 0.000 description 6
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000002329 infrared spectrum Methods 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 229920002307 Dextran Polymers 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229930182470 glycoside Natural products 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 5
- 238000002211 ultraviolet spectrum Methods 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000005273 aeration Methods 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 108010047754 beta-Glucosidase Proteins 0.000 description 2
- 102000006995 beta-Glucosidase Human genes 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- OZBAVEKZGSOMOJ-MIUGBVLSSA-N glycitin Chemical compound COC1=CC(C(C(C=2C=CC(O)=CC=2)=CO2)=O)=C2C=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OZBAVEKZGSOMOJ-MIUGBVLSSA-N 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 150000002772 monosaccharides Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical group N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 2
- HXBYBCASAVUYKF-GVYWOMJSSA-N (4r,5s,6r,7r)-4,5,6,7,8-pentahydroxyoctane-2,3-dione Chemical compound CC(=O)C(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO HXBYBCASAVUYKF-GVYWOMJSSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 1
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 1
- XJTZHGNBKZYODI-UHFFFAOYSA-N Glycitin Natural products OCC1OC(Oc2ccc3OC=C(C(=O)c3c2CO)c4ccc(O)cc4)C(O)C(O)C1O XJTZHGNBKZYODI-UHFFFAOYSA-N 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000002031 ethanolic fraction Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 1
- 235000008466 glycitein Nutrition 0.000 description 1
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Definitions
- the present invention relates to low and medium molecular weight isoflavone- ⁇ -D-glucan produced by submerged liquid culture of Agaricus blazei, a method of producing the isoflavone- ⁇ -D-glucan using autolysis enzyme of Agaricus blazei mycelia, and use of the isoflavone- ⁇ -D-glucan for anti-cancer and immunoenhancing effect.
- Conventional anti-cancer agents have much toxicity to affect normal cells since they are lack of specificity to cancer cells, which results in a variety adverse effects such as depilation, lowering of immunity and liver function, etc.
- ⁇ -D-glucan is a main bioactive component in mushroom. It is found that the anti-cancer activity of mushroom derives from the activation of immunocyte by ⁇ -D-glucan to delay the progress of cancer and to prevent the transition of cancer. Accordingly, ⁇ -D-glucan may be used along with cancer treatment to improve the effect.
- ⁇ -D-glucan extract from mycelium culture of mushroom
- AHCC which is imported from Japan
- arabinoxylan which is extract from Lentinus edodes mycelia
- Mesima-EX HAN KOOK SIN YAK Corp, Korea
- the extracts of mushroom mycelium culture commercialized by this time have not been distributed on a large scale since the extraction process costs very high.
- the amount of extract of mushroom mycelium culture that is, the amount of polysaccharides depends on the cultivation period of mushroom and the growth rate of mycelia. In general, the cultivation period of Lentinus edodes, Phellinus linteus, Ganoderma lucidum, etc. is long and the growth of mycelia is slow, which limits the amount of extracts.
- the polysaccharides extracted from mycelium culture require to be hydrolyzed to medium or low molecular weight polysaccharides in order to be absorbed easily in the body.
- the enzyme for the hydrolyzation is hard to obtain, which makes the cost high.
- the method of separating and purifying the medium or low molecular weight polysaccharides produced from the hydrolyzation has technical difficulty, so that the yield is very low.
- Isoflavone contained mainly in soybean, exists as aglycon form (e.g., daidzein, genistein or glycitein), as glycoside form thereof (e.g., daidzin, genistin or glycitin), as acetylglycoside thereof (e.g., acetylglucose), or as malonylglycoside thereof (e.g., malonylglucose). It is found that isoflavone has anti-mutagenic and anti-cancer effect. The anti-cancer effect of isoflavone is mainly caused by genistein in the aglycon form, and the glycoside form is not known to have anti-cancer effect.
- aglycon form e.g., daidzein, genistein or glycitein
- glycoside form thereof e.g., daidzin, genistin or glycitin
- a method of producing isoflavone- ⁇ -D-glucan which comprises the steps of:
- the step of separating the high molecular weight isoflavone- ⁇ -D-glucan from the liquid culture of Agaricus blazei mycelia comprises:
- ethanol is preferably added in the concentration of 80%.
- the step of separating an autolysis enzyme from a separate liquid culture of Agaricus blazei mycelia comprises:
- the autolysis enzyme is preferably added to the high molecular weight isoflavone- ⁇ -D-glucan at pH 4.5-5.5.
- the step of activating an autolysis enzyme from the liquid culture of Agaricus blazei mycelia is carried out by adjusting the pH of culture medium to pH 4.5-5.5 for 1-3 hours.
- the low and medium molecular weight isoflavone- ⁇ -D-glucan produced from a liquid culture of Agaricus blazei mycelia is used as anti-cancer and immunoenhancing agent.
- polysaccharides having anti-cancer activity have been obtained from Basidiomycetes by extracting fruit body or mycelium cultured in solid medium or liquid medium.
- solid culture a long period of time is required for culturing and the process of extracting the anti-cancer polysaccharides is difficult.
- the amount of polysaccharides extracted from fruit body is very low, and therefore, it is difficult to produce them on a large scale.
- liquid culture a short period of time is required, and it is possible to culture in a settled condition, which enables mycelia including a regular content of polysaccharides to be obtained on a large scale at low cost.
- the present invention is characterized in using Agaricus blazei mycelia as the mushroom mycelia cultured in liquid media containing isoflavone to produce low and medium molecular weight isoflavone- ⁇ -D-glucan.
- low and medium molecular weight isoflavone- ⁇ -D-glucan is prepared from high molecular weight isoflavone- ⁇ -D-glucan extracted from liquid culture of Agaricus blazei mycelia, in order to enhance internal absorption thereof.
- autolysis enzyme secreted by Agaricus blazei mycelia is used to digest the high molecular weight isoflavone- ⁇ -D-glucan at an optimum condition for the activity of the enzyme.
- Agaricus blazei mycelium is selected for its highest activity of autolysis enzyme.
- Low and medium molecular weight isoflavone- ⁇ -D-glucan produced according to the present invention may be used for anti-cancer and immunoenhancing effect.
- the isoflavone- ⁇ -D-glucan of the present invention is very effective in killing cancer cells and shows no toxic effect on normal cells. It is found that isoflavone in free form has anti-cancer effect. However, the anti-cancer effect of isoflavone- ⁇ -D-glucan as glycoside has never been found before the present invention.
- Low and medium molecular weight isoflavone- ⁇ -D-glucan produced according to the present invention is characterized to have anti-cancer effect as well as immunoenhancing effect.
- the anti-cancer effect of the low and medium molecular weight isoflavone- ⁇ -D-glucan is remarkably increased with immunoenhancing effect.
- FIG. 1 shows a process of preparing a low and medium molecular weight isoflavone- ⁇ -D-glucan according to the present invention
- FIG. 2 is HPLC chromatograms of the extract of liquid culture of Agaricus blazei mycelia treated with various concentrations of ethanol solution.
- FIG. 3 shows fractionation of the precipitate of the liquid culture of Agaricus blazei mycelia by DEAE column chromatography
- FIG. 4 is UV spectrum of DEAE column fraction # 2 (tube # 8 ) at 225-445 nm;
- FIG. 5 shows SDS-PAGE pattern of tubes # 8 and # 14 ;
- FIG. 6 shows TLC pattern of 80 EP reacted with autolysis enzyme
- FIGS. 7 a and 7 b are HPLC chromatograms of each fraction containing autolysis enzyme separated from HPLC (TSK column) before and after being treated with 80 EP;
- FIG. 8 is HPLC chromatograms of the products from 80 EP treated with tube # 8 , which are detected with UV detector and RI detector;
- FIG. 9 shows TLC pattern of soybean powder and its acid hydrolyzate
- FIG. 10 is UV/VIS spectra of autolysis enzyme-treated 80 EP
- FIGS. 11 a, 11 b and 11 c are IR spectra of TLC bands of FIG. 9 ;
- FIG. 12 shows another process of preparing a low, and medium molecular weight isoflavone- ⁇ -D-glucan according to the present invention
- FIG. 13 is a graph showing molecular weight of low and medium molecular weight isoflavone- ⁇ -D-glucan according to the present invention calculated by comparing with dextran standard and displayed in log scale;
- FIG. 14 is IR spectrum of low and medium molecular weight isoflavone- ⁇ -D-glucan according to the present invention.
- FIG. 15 is H-NMR spectrum of low and medium molecular weight isoflavone- ⁇ -D-glucan according to the present invention.
- FIG. 16 is UV spectrum of low and medium molecular weight isoflavone- ⁇ -D-glucan according to the present invention.
- FIG. 17 shows the composition of monosaccharide of low and medium molecular weight isoflavone- ⁇ -D-glucan according to the present invention
- FIG. 18 shows the cytotoxic effects of the products of 80 EP treated with autolysis enzyme on human colon cancer Caco-2 cells
- FIG. 19 shows the comparison of cytotoxicity of 80 EP treated with tube # 8 with various concentrations.
- FIG. 20 shows the effect of 80 EP treated with autolysis enzyme on the reduction of ICR female mouse body weight induced by lipopolysaccharide (LPS).
- LPS lipopolysaccharide
- FIG. 1 shows a process of preparing a low and medium molecular weight isoflavone- ⁇ -D-glucan according to the present invention.
- the process comprises step (1) of producing high molecular weight isoflavone- ⁇ -D-glucan by culturing AB mycelia in a liquid medium containing isoflavone.
- the high molecular weight isoflavone- ⁇ -D-glucan is separated from the liquid culture of AB mycelia by extracting the liquid culture with boiling water, concentrating the extract, adding ethanol to the concentrated extract to make precipitation and separating the precipitate.
- 80% ethanol has the maximum effect on obtaining high molecular weight isoflavone- ⁇ -D-glucan.
- the process of preparing a low and medium molecular weight isoflavone- ⁇ -D-glucan according to the present invention comprises step (3) of separating autolysis enzyme from a separate liquid culture of AB mycelia.
- the next process of preparing isoflavone- ⁇ -D-glucan is step (4) of adding the autolysis enzyme obtained from the liquid culture of AB mycelia to the high molecular weight isoflavone- ⁇ -D-glucan to produce a low and medium molecular weight isoflavone- ⁇ -D-glucan.
- the autolysis enzyme has the best activity in the condition of pH 4.5 to 5.5 and at the temperature of 53° C. for 1 to 3 hours. Considering the viscosity of product, the reaction for 3 hours appeared to be optimum. However, the effect of reaction time on producing low and medium molecular weight isoflavone- ⁇ -D-glucan had no difference between 3 hours and 1 hour. Accordingly, the reaction is preferable to be carried out for 1 hour.
- the process of preparing isoflavone- ⁇ -D-glucan according to the present invention further comprises step (5) of separating and purifying the low and medium molecular weight isoflavone- ⁇ -D-glucan.
- the low and medium molecular weight isoflavone- ⁇ -D-glucan is separated by DEAE column chromatography.
- the separated fraction is concentrated by vacuum concentrator and then separated by silica gel column chromatography.
- FIG. 12 shows another process of preparing a low and medium molecular weight isoflavone- ⁇ -D-glucan according to the present invention.
- steps 6 and 8 are carried out by the same procedure of steps 1 and 5 in FIG. 1 .
- step 7 in FIG. 12 are carried out by adjusting the pH of culture medium to 4.5-5.5 for 1-3 hours instead of treating the high molecular weight isoflavone- ⁇ -D-glucan with separated autolysis enzyme.
- Agaricus blazei (AB), Pleurotus ostreatus (PO), Coprinus comatus (CC), Lentinus edodes (LE), Phellinus linteus (PL) and Ganoderma lucidum (GL) were cultured in liquid culture medium at 25° C. for three days in the condition of 1 v/v/m aeration.
- Liquid culture of each strain (10 ml) and polysaccharides prepared from the liquid culture were added with 80% ethanol (80 EP). The mixtures were then incubated at 53° C. and 63° C. for five hours. Degree of autolysis was determined by measuring the change of viscosity of 80 EP before and after the reaction. The following Table 1 shows the change of viscosity.
- AB has the highest value of 3,470 ml/sec in the change of viscosity ( ⁇ viscosity/hour). PO and CC also have rather higher values of 120 and 104 ml/sec. As a result, it is considered that AB has the highest degree of autolysis compared to other strains.
- the culture medium contained soybean powder or natural source including soybean powder. Natural isoflavone separated from soybean or synthetic isoflavone may also be used. The liquid medium were added with brown sugar as carbon source and inorganic salts, and then autoclaved at 120° C. for 30 minutes.
- AB mycelia were inoculated in the liquid culture medium containing isoflavone and cultured with aeration or stirring for 1 to 7 days to produce high molecular weight isoflavone- ⁇ -D-glucan.
- the molecular weight of the high molecular weight isoflavone- ⁇ -D-glucan was at least 30,000.
- Liquid culture of AB mycelia was extracted with boiling water at 100° C. for 10 hours, and the extract was autoclaved at 121° C. for 1 hour.
- the extract of liquid culture of AB mycelia was treated with 80% ethanol to make precipitation and then centrifuged to remove supernatant.
- the precipitate was separated to obtain high molecular weight isoflavone with ⁇ -D-glucan having the molecular weight of at least 100,000.
- the extract of liquid culture of AB mycelia was suspended in ethanol to prepare 10 to 80% ethanol solution to induce precipitation. Each precipitate was separated and then applied to Biosep S-2000 column.
- FIG. 2 is HPLC chromatograms of the extract of liquid culture of Agaricus blazei mycelia treated with various concentrations of ethanol solution (40, 50, 60, 70 and 80% ethanol) and then separated with Biosep S-2000 column.
- the chromatogram on the right side below represents the chromatogram of total extract of liquid culture of AB mycelia.
- horizontal axis represents time (minutes) and vertical axis represents length (mAU).
- the high molecular weight isoflavone- ⁇ -D-glucan obtained by treating 80% ethanol to the liquid culture of AB mycelia to induce precipitation, hereinafter referred to ‘80 EP (80% ethanol precipitate)’, shows similar chromatograph pattern to 70 EP, both showing peaks at RT (retention time) 2.2 and 3.
- 80 EP the peak at RT 3 is higher than the peak at RT 2.2, while two peaks at RT 3 and 2.2 have similar heights to those of 70 EP.
- Other fractions have similar patterns to the total extract of liquid culture of AB mycelia, showing peaks at RT 2.2, 3 and 3.6.
- 80 EP has higher amount of high molecular weight isoflavone- ⁇ -D-glucan than other ethanol precipitates have. Further, 80 EP does not have unnecessary peaks, such as the peak at RT 3.6 which is found in other EP. Accordingly, 80 EP is used to increase the yield of isoflavone- ⁇ -D-glucan according to the present invention.
- the separation of autolysis enzyme was carried out by filtrating the liquid culture of AB mycelia at reduced pressure. TCA (trichloroacetic acid) was added to the filtrate to the concentration of 10% and the mixture was placed at 4° C. for 24 hours. The resultant was centrifuged at 4° C. and 10,000 rpm for 15 minutes to obtain the precipitate.
- TCA trichloroacetic acid
- the precipitate was further fractionated by DEAE (diethylaminoethyl) column chromatography and each fraction was determined its UV absorbance at 280 nm.
- FIG. 3 shows fractionation of the precipitate of the liquid culture of Agaricus blazei mycelia by DEAE column chromatography.
- horizontal axis represents number of each fraction and vertical axis represents UV absorbance at 280 nm.
- UV absorbance of each fraction was monitored and eight fractions were obtained showing UV absorbance at 280 nm.
- Fraction # 2 (tube # 8 ) showed the maximum UV absorbance.
- tube # 8 showed the highest activity. Accordingly, tube # 8 was used for treating the 80 EP obtained in Example 2 to prepare low and medium molecular weight isoflavone- ⁇ -D-glucan.
- FIG. 4 is UV spectrum of DEAE column fraction # 2 (tube # 8 ) at 225-445 nm.
- horizontal axis represents wavelength
- vertical axis represents absorbance
- the left box shows the numerical value of wavelength and absorbance.
- fraction # 2 (tube # 8 ) has the maximum UV absorbance at 270 nm.
- the fraction of DEAE column chromatography was added to 80 EP obtained in Example 2.
- the production of low and medium molecular weight isoflavone- ⁇ -D-glucan from high molecular weight isoflavone- ⁇ -D-glucan was confirmed by using TSK column and C18 column.
- TSK column chromatography H 2 O was used as mobile phase at 1 ml/min.
- C18 column chromatography MeOH:1 mM ammonium acetate (6:4) was used as mobile phase at 1 min.
- Isoflavone was identified at UV 257 nm and 267 nm.
- RI detector was used to identify ⁇ -D-glucan.
- tube # 8 obtained in Example 3 showed maximum autolysis activity
- molecular weight of the protein contained in tube # 8 was determined by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis).
- FIG. 5 shows SDS-PAGE pattern of tubes # 8 and # 14 .
- SM of horizontal axis is size marker and vertical axis represents molecular weight of the protein used as size marker.
- molecular weight of the protein in tube # 8 corresponds to 7 kDa, which shows that molecular weight of autolysis enzyme is about 7 kDa.
- the high molecular weight isoflavone- ⁇ -D-glucan obtained by treating 80% ethanol to the liquid culture of AB mycelia (80 EP) was added with 10 ml of autolysis enzyme separated from DEAE column in Example 3. The mixture was placed at 53° C. for 1 hours to produce a low and medium molecular weight isoflavone- ⁇ -D-glucan.
- the molecular weight of obtained isoflavone- ⁇ -D-glucan was less than about 30,000.
- the liquid culture of AB mycelia and 80 EP were reacted at each conditions of pH 4.5, 5.5, 6.5 and 7.5 and temperature of 53° C. and 63° C. for 1, 3, 5, 15 and 24 hours and the viscosity was measured in each condition.
- Table 2 shows the viscosity of liquid culture of AB mycelia reacted with autolysis enzyme. As shown in Table 2, the autolysis enzyme obtained from AB mycelia has maximum activity at the condition of pH 4.5 to 5.5 and the temperature of 53° C. for 3 hours of reaction. TABLE 2 53° C. 63° C.
- Free sugars or polymeric sugar has no UV absorbance. Therefore, in order to examine that an area separated by TLC has the material having UV absorbance, sugars, or sugars having UV absorbance, the separated band was detected with UV lamp and also analyzed by color development with diphenylamine aridine phosphate (DAP).
- DAP diphenylamine aridine phosphate
- the fraction separated by silica gel column chromatography was developed by TLC (Silica gel 60F-254 plate, 5 ⁇ 10 cm).
- the mobile phase was butanol:ethanol:H 2 O (5:3:3) (v/v/v).
- the separated band was treated by DAP and UV lamp was used to identify the material having UV absorbance.
- FIG. 6 shows TLC pattern of 80 EP reacted with autolysis enzyme.
- DP7 represents maltoheptose; DP4, maltotetrose; DP3, maltotriose; DT 5,000, dextran 5,000; DT 12,000, dextran 12000; DT 25,000, dextran 25,000; P+80% ethanol, 80 EP treated with autolysis enzyme; and 80% ethanol, 80 EP without treatment with autolysis enzyme.
- the vertical axis of FIG. 6 represents Rf value which means the separation of material.
- low molecular weight polysaccharides (DP7 or less) move, while medium or higher molecular weight polysaccharides (MW 5,000) do not moved.
- low molecular weight sugars (DP3 or less) showing color development by DAP are mixed with the materials having UV absorbance and showing color development by DAP.
- medium or higher molecular weight polysaccharides showing no movement have UV absorbance
- sugars of DP7 also have UV absorbance.
- the materials having UV absorbance only are also included herein.
- Bio-Sep S2000 column (mobile phase; 20 mM sodium phosphate), TSK column (mobile phase; H 2 O) and C18 column (mobile phase; MeOH:1 mM ammonium acetate (6:4)) were used. Flow rate was 1 ml/min in all cases. UV detector (UV 257 nm, 267 nm, 280 nm) and RI detector was used.
- FIGS. 7 a and 7 b are HPLC chromatograms of each fraction containing autolysis enzyme separated from HPLC (TSK column) before and after treating with 80 EP.
- the horizontal axis represents time (minutes) and the vertical axis represents length (mAU).
- the left panel shows HPLC chromatograms of each fraction of # 2 , # 8 , # 14 , # 25 , # 35 , # 65 and # 83 treated with 80 EP a shows HPLC chromatograms of each fraction.
- the uppermost chromatogram of 80 EP has four peaks.
- the fraction of tube # 8 showed different pattern from that of 80 EP, which represents that new product has been formed.
- the original pattern of 80 EP was maintained, which means that digestion has not been carried out. Accordingly, it is considered that the high molecular polysaccharides contained in 80 EP have been digested into medium or low molecular weight polysaccharides by the reaction with the fraction of tube # 8 .
- the digest obtained from 80 EP treated with autolysis enzyme (tube # 8 ) was separated with HPLC, and then monitored by UV detector and RI detector simultaneously.
- FIG. 8 are HPLC chromatograms of the products from 80 EP treated with tube # 8 , which are detected with UV detector and RI detector.
- left panel A shows the result of RI detector and right panel B shows the result of UV detector (267 nm).
- RT 8.8 peak is detected by both UV detector and RI detector, and the other peaks are detected either UV detector or RI detector.
- polysaccharides are coupled with another material (having UV absorbance) which is considered to be isoflavone having UV absorbance.
- FIG. 9 shows TLC pattern of soybean powder (SP) and its acid hydrolyzate (SPH).
- SP means precipitate of 80 EP obtained from the liquid culture of AB mycelia and then treated again with 80% ethanol; APH, acid-hydrolyzate of AP; AS, supernatant of the above 80 EP; ASH, hydrolyzate of AS; SP, soybean powder consisting of culture media; SPH, hydrolyzate of SP.
- G genistein
- D diaidzein
- GT geneistein standard
- all the samples obtained from SP contain the materials having UV absorbance (RF 0.999, 0.542, 0.306) alone (especially, G and D, etc.) and do not contain the materials detected in UV lamp and DAP simultaneously, which shows that SP provides the materials having UV absorbance alone.
- the fraction obtained from AP has the material detected in UV and DAP simultaneously (Rf 0.542, 0.014), which means that the material is not contained in culture medium but produced during the liquid culture of AB mycelia by bioconversion.
- FIG. 10 is UV/VIS spectra of autolysis enzyme-treated 80 EP and FIGS. 11 a, 11 b and 11 c are IR spectra of TLC bands of FIG. 9 . As shown in FIGS. 10, 11 a, 11 b and 11 c, all the spectra are similar to those of G and D, which means that they are glycosides of G or D. It is considered that the materials are produced during the liquid culture by bioconversion.
- Isoflavone- ⁇ -D-glucan which is finally separated and purified according to the present invention (A) and isoflavone- ⁇ -D-glucan hydrolyzed by enzyme ( ⁇ -glucosidase and megazyme kit) (B) were analyzed by HPLC (C18 column, mobile phase; MeOH: 1 mM ammonium acetate (6:4), flow rate; 1 ml/min).
- Table 3 shows the content of free genistein and daidzein in A and B. TABLE 3 Genistein Daidzein isoflavone- ⁇ -D- — — glucan(A) isoflavone- ⁇ -D-glucan 150 mg/g dry weight 28.2 mg/g dry weight hydrolyzate (B)
- Molecular weight of low and medium molecular weight isoflavone- ⁇ -D-glucan was determined by HPLC equipped with TSK column (PDA-100 UV detector and RI detector, P-680 pump, ASI-100 fraction collector, Dionex). Mobile phase was triple distilled water and flow rate was 1 ml/min.
- FIG. 13 is a graph showing molecular weight of low and medium molecular weight isoflavone- ⁇ -D-glucan according to the present invention calculated by comparing with dextran standard and displayed in log scale. As shown in FIG. 13 , molecular weight of low and medium molecular weight isoflavone- ⁇ -D-glucan was about 25,000.
- FIG. 14 is IR spectrum of low and medium molecular weight isoflavone- ⁇ -D-glucan according to the present invention.
- the characteristic peaks were 495-656 cm ⁇ 1 (strong, broad), 1014 cm ⁇ 1 (strong, narrow), 1109 cm ⁇ 1 (weak, narrow), 1402.0, 1450.8, 1472.7 cm ⁇ 1 (weak, broad), 1642.6 cm ⁇ 1 (strong, narrow), 2097.0-2112.0 cm ⁇ 1 (medium weak, broad), 2390 cm ⁇ 1 (very weak, broad), 2843 cm ⁇ 1 (medium, narrow in OH absorbance ⁇ 3000 cm ⁇ 1 ), 3173.0-3648 cm ⁇ 1 (broad in OH absorbance ⁇ 3000 cm ⁇ 1 ), the characteristic peaks shown in IR spectrum of G or D standard.
- FIG. 15 is H-NMR spectrum and FIG. 16 is UV spectrum of low and medium molecular weight isoflavone- ⁇ -D-glucan according to the present invention.
- maximum absorbance was appeared in 267 nm, likewise that of G. Accordingly, it is considered that RT 8.8 peak indicates ⁇ -D-glucan containing mostly G among isoflavone.
- Sample was added with 5 ml of phosphate buffer (20 mM, pH 6.5) and then digested by megazyme kit ( ⁇ -glucosidase; 0.2 U, 0.1 ml) and licenase (10 U, 0.2 ml).
- the digest was analyzed by HPLC (Rezo RCM-monosaccharide column, 200 ⁇ 10 mm) to identify the composition of sugars.
- FIG. 17 shows the composition of monosaccharide of low and medium molecular weight isoflavone- ⁇ -D-glucan according to the present invention (RT 8.8).
- the low and medium molecular weight isoflavone- ⁇ -D-glucan according to the present invention includes ⁇ -D-glucose, D-fructose and ribose.
- soybean or soybean powder 40 g of soybean or soybean powder was added with 10 g of protease and 10 g of cellulase and then digested at 60° C. and 200 rpm for 1 to 5 hours.
- the digest may be used with or without addition of 10 to 1000 mg of natural isoflavone separated from vegetables or synthetic isoflavone.
- 220 g of brown sugar, 3 g of ribose and inorganic salts (10 g of MgSO 4 , 10 g of KH 2 PO 4 ) were added thereto and then water was added to make the total volume 1 l.
- the mixture was autoclaved at 121° C. for 1 hour to make liquid culture medium.
- Agaricus blazei mycelia were inoculated into the liquid medium, and then cultured upon shaking or aeration at 25-35° C. for 1-7 days.
- the culture obtained in Preparation Example 1 was autoclaved at 121° C. for 1 hour, filtrated through diatomite, and then concentrated to 1/10 volume under vacuum. 200 g of the concentrate was added with ethanol to be 80% ethanol solution and then mixed. The mixture was placed at 4° C. for 24 hours to induce precipitation. The precipitated liquid was centrifuged at 10,000 rpm for 10 minutes and the supernatant was removed to obtain 3.8 g of the precipitate containing ⁇ -D-glucan having the molecular weight of 100,000 or more (80 EP).
- Liquid culture of AB mycelia was filtrated under reduced pressure and the filtrate was mixed with TCA to make 10% TCA solution. The mixture was placed at 4° C. for 24 hours and then centrifuged at 4° C. and 10,000 rpm for 15 minutes to separate the precipitate.
- the precipitate was dissolved in 50 mM sodium acetate buffer (pH 5.0) and then separated by DEAE column (2 cm, 110 cm) to collect factions by 10 ml.
- the mobile phase was 20 mM sodium phosphate buffer (20 mM NaH 2 PO 4 and 20 mM Na 2 HPO 4 , pH 7.0).
- S-180 cells were maintained and subcultured at 37° C. in a humidified CO 2 incubator (95% air-5% CO 2 ).
- the complete medium for cell maintenance consisted of DMEM (Dulbecco's modified Eagle's medium) containing 10% horse serum, 100 U/ml penicillin and 100 ⁇ l/ml streptomycin. When cells were 80% confluent, the medium was changed every two days.
- cells were plated in complete medium in 24-well plates. All wells were treated with 5 ⁇ 10 4 cells/ml DMEM and then with each sample or control. The treated well plates were cultured in 5% CO 2 incubator at 37° C. for 48 hours. Alive cells were dyed by 0.2% tryphane blue and the number of viable cells was determined by counting in a hemocytometer to calculate ED 50 .
- Table 4 shows the toxicity of the sample from 80 EP fraction treated with autolysis enzyme (tube # 8 ) against S-180 cancer cells. As shown in Table 4, the cell number of control was 23.7 ⁇ 10 4 cells/ml after 48 hours of incubation. The cell numbers treated with autolyzed AB in each concentration of 10, 20 and 30 ⁇ g/ml were 7.5 ⁇ 10 4 , 6.0 ⁇ 10 4 and 5.5 ⁇ 10 4 cells/ml, respectively, resulting in 0.9 ⁇ g/ml of ED 50 .
- the cell numbers treated with AB without autolysis in each concentration of 10, 20 and 30 ⁇ g/ml were 11.0 ⁇ 10 4 , 9.5 ⁇ 10 4 and 8.5 ⁇ 10 4 cells/ml, respectively, resulting in 2.1 ⁇ g/ml of ED 50 .
- the result shows that the cytotoxicity increases in the sample treated with autolysis enzyme. Accordingly, it is considered that cytotoxic substances are generated from 80 EP fraction by the treatment of autolysis enzyme.
- mice 7 week-old female ICR (Institute for Cancer Research) mice were obtained from Life Science (Taegu, Korea). S-180 cells were supplied by Korean Cell Line Bank (Seoul, Korea). The culture medium for S-180 was obtained by GIBCO and other reagents used were first grade.
- the ICR mice were grouped by 10 mice so that each group had equal mean body weight and then each group was put into a cage. The mice were raised freely with food and water for 1 week in an animal house at controlled room temperature and relative humidity. S-180 cells were subcultured as ascites type in ICR mice, and the tumor cells were harvested from the abdominal cavities of the mice 7 days after the implantation. 0.1 ml of S-1 80 cells (1 ⁇ 10 7 cells/ml PBS) was transplanted subcutaneously into the abdomen of each mice to induce ascite cancer. 0.1 ml of test sample, dissolved or suspended in PBS (0.01M, pH 7.0) in adequate concentrations, was injected intraperitoneally every two days for 2 weeks, starting 24 hours after tumor implantation. After the intraperitoneal injection of S-180, the weight of mouse and the amount of feed intake were measured every three days for 40 days. The number of survived mice and the number of survival days were also measured.
- Table 5 shows the number of survived mice and survival days of control group, the group treated with 80 EP, and the group treated with autolyzed 80 EP.
- the average survival days of control group was 19.2 days, while it was extended to 26.9 days (lengthen the life span by 40%) by the treatment of autolyzed AB and 3 mice were still alive after 40 days.
- the treatment of AB also lengthened survival days compared with control but less effective than autolyzed AB.
- TABLE 5 Treatment Mean survival days Survival rate (%) Survived mice Control 19.2 100 0/10 AB 22.3 116 0/10 Autolyzed AB 26.9 140 3/10
- Table 6 shows the cytotoxicity of the samples from 80 EP fraction treated with or without autolysis enzyme (tube # 8 ) against Hela cell (uterine cervix cancer cell line). As shown in Table 6, the cell number of Hela cells was 20.1 ⁇ 10 4 cells/ml after 48 hours incubation. ED 50 values of AB and autolyzed AB were 5.6 and 0.9 ⁇ g/ml, respectively. Accordingly, it is considered that autolyzed AB has strong cytotoxicity and cytotoxic substances are produced from 80 EP fraction by the treatment of autolysis enzyme.
- Table 7 shows the cytotoxicity of the samples from 80 EP fraction treated with or without autolysis enzyme (tube # 8 ) against MCF-7 cell (breast cancer cell line). As shown in Table 7, the cell number of MCF-7 cells was 21.5 ⁇ 10 4 cells/ml after 48 hours incubation. ED 50 values of AB and autolyzed AB were 5.8 and 1.2 ⁇ g/ml, respectively, which were similar to those for Hela cells.
- FIG. 18 shows the cytotoxic effects of the products of 80 EP treated with autolysis enzyme on human colon cancer Caco-2 cells.
- the height of bar represents percentage of cell number after the treatment of autolysis enzyme as compared with control.
- 80 EP fraction without treatment of autolysis enzyme shows 85.7% of viability, that is, 14% of cytotoxicity.
- tube # 4 and tube # 14 treated with autolysis enzyme show 37% and 33% of cytotoxicity, respectively.
- Other samples also show toxicity at a lesser extent.
- FIG. 19 shows the comparison of cytotoxicity of 80 EP treated with tube # 8 with various concentrations.
- sample A is 80 EP without treatment of autolysis enzyme and sample B is 80 EP treated with autolysis enzyme.
- the height of bar represents percentage of cell number after the treatment of autolysis enzyme as compared with control, in which concentration of white bar, dotted bar and shaded bar are 1, 5 and 10 mg, respectively.
- concentration of white bar, dotted bar and shaded bar are 1, 5 and 10 mg, respectively.
- concentration of white bar, dotted bar and shaded bar are 1, 5 and 10 mg, respectively.
- cytotoxicity was not affected by the increase of concentration
- sample B cytotoxicity increased to 2, 23 and 42%, respectively, with the treatment of autolysis enzyme by 1, 5 and 10 mg.
- mice Female ICR mice (6-7 weeks of age) were housed in polycarbonated cage (4 mice/cage) and raised with feeding pellet fodder for mouse for 1 weeks and those of 28 ⁇ 1 g body weight were selected for experiment. All mice were raised freely with food and water in an animal house at 22 ⁇ 1° C. room temperature and 50% relative humidity maintaining light-and-dark cycle of 12 hour interval.
- mice were subjected to one of the following treatments for 14 days: 0 (control), 1, 2 and 4 mg/g body weight/0.2 ml distilled water. Samples were injected per os. At the end of 14 consecutive feeding days, mice were weighted and injected intraperitoneally with 1 mg/kg body weight of lipopolysaccharide (LPS, Sigma Chemical Co.) in sterile HEPES buffer (Sigma Chemical Co.) or HEPES buffer alone. All mice were weighted 4, 8, 12, 24, 48 and 72 hours post injection.
- LPS lipopolysaccharide
- FIG. 20 shows the effect of 80 EP treated with autolysis enzyme on the reduction of ICR female mouse body weight induced by lipopolysaccharide (LPD).
- (1) represents control group
- (2), (3) and (4) represent the groups treated with 1, 2 and 4 mg of autolyzed 80 EP, respectively
- (5), (6) and (7) represent the groups treated with 1, 2 and 4 mg of 80 EP without treatment of autolysis enzyme.
- LPS a complex of lipid and polysaccharide with a covalent bond, forms an endotoxin consisting in outer membrane component of Gram negative bacteria.
- LPS has various biological activity and is called endotoxin.
- LPS of bacteria is recognized as the signal of infection by the immune system of host. Accordingly, immune ability may be presumed by determining the reduction of body weight after the treatment of LPS.
- the AB sample (80 EP without treatment of autolyzed enzyme) was less effective for the suppression of body weight reduction, compared to autolyzed AB sample.
- the present invention provides low and medium molecular weight isoflavone- ⁇ -D-glucan produced by submerged liquid culture of Agaricus blazei, a method of producing the isoflavone- ⁇ -D-glucan using autolysis enzyme of Agaricus blazei mycelia, and use of the isoflavone- ⁇ -D-glucan for anti-cancer and immunoenhancing effect.
- low and medium molecular weight isoflavone- ⁇ -D-glucan is prepared from high molecular weight isoflavone- ⁇ -D-glucan extracted from liquid culture of Agaricus blazei mycelia, by using autolysis enzyme secreted by Agaricus blazei mycelia at an optimum condition for the activity of the enzyme.
- the process requires a short period of time and enables the product to be obtained on a large scale at low cost.
- Low and medium molecular weight isoflavone- ⁇ -D-glucan of the present invention has anti-cancer effect as well as immunoenhancing effect without toxic effect on normal cells.
- the anti-cancer effect is remarkably increased with immunoenhancing effect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
The present invention relates to low and medium molecular weight isoflavone-β-D-glucan produced by submerged liquid culture of Agaricus blazei, a method of producing the isoflavone-β-D-glucan using autolysis enzyme of Agaricus blazei mycelia, and use of the isoflavone-β-D-glucan for anti-cancer and immunoenhancing effect.
Description
- This application is a divisional application of U.S. patent application Ser. No. 10/890,537 filed Jul. 12, 2004, which claimed the priority of Korean Patent Application No. 2003-67439, filed Sep. 29, 2003, in the Korean Intellectual Property Office, the contents of which are incorporated by reference herein in their entirely.
- The present invention relates to low and medium molecular weight isoflavone-β-D-glucan produced by submerged liquid culture of Agaricus blazei, a method of producing the isoflavone-β-D-glucan using autolysis enzyme of Agaricus blazei mycelia, and use of the isoflavone-β-D-glucan for anti-cancer and immunoenhancing effect.
- Cancer holds the most fatal disease in the statistics of mortality, so that anti-cancer agents have been a matter of continued concern. Conventional anti-cancer agents have much toxicity to affect normal cells since they are lack of specificity to cancer cells, which results in a variety adverse effects such as depilation, lowering of immunity and liver function, etc.
- Considering the above, various researches have been carried out to obtain natural anti-cancer agents from all sorts of food having no or little adverse effect. As a result, it is revealed that β-D-glucan obtained from mushroom mycelia and isoflavone contained in soybean, etc. have anti-cancer effect.
- β-D-glucan is a main bioactive component in mushroom. It is found that the anti-cancer activity of mushroom derives from the activation of immunocyte by β-D-glucan to delay the progress of cancer and to prevent the transition of cancer. Accordingly, β-D-glucan may be used along with cancer treatment to improve the effect.
- β-D-glucan, extract from mycelium culture of mushroom, is produced on a commercial scale in some advanced countries. For example, AHCC, which is imported from Japan, is produced by mixing extracts from mycelium cultures of seven mushrooms and is distributed through sales network for hospital to cancer patients. Further, arabinoxylan, which is extract from Lentinus edodes mycelia, is distributed in the US. In Korea, extract of Phellinus linteus mycelia, which is produced on a commercial scale by the trade name of Mesima-EX (HAN KOOK SIN YAK Corp, Korea), is on the clinical test.
- The extracts of mushroom mycelium culture commercialized by this time have not been distributed on a large scale since the extraction process costs very high. The amount of extract of mushroom mycelium culture, that is, the amount of polysaccharides depends on the cultivation period of mushroom and the growth rate of mycelia. In general, the cultivation period of Lentinus edodes, Phellinus linteus, Ganoderma lucidum, etc. is long and the growth of mycelia is slow, which limits the amount of extracts.
- The polysaccharides extracted from mycelium culture require to be hydrolyzed to medium or low molecular weight polysaccharides in order to be absorbed easily in the body. However, the enzyme for the hydrolyzation is hard to obtain, which makes the cost high. Further, the method of separating and purifying the medium or low molecular weight polysaccharides produced from the hydrolyzation has technical difficulty, so that the yield is very low.
- Isoflavone, contained mainly in soybean, exists as aglycon form (e.g., daidzein, genistein or glycitein), as glycoside form thereof (e.g., daidzin, genistin or glycitin), as acetylglycoside thereof (e.g., acetylglucose), or as malonylglycoside thereof (e.g., malonylglucose). It is found that isoflavone has anti-mutagenic and anti-cancer effect. The anti-cancer effect of isoflavone is mainly caused by genistein in the aglycon form, and the glycoside form is not known to have anti-cancer effect.
- Considering the above, efforts have continued for the development of an anti-cancer agent with immunoenhancing effect, without affecting adversely on normal cell, and a method of preparing the agent in great quantities with low cost.
- It is an object of the present invention to provide a glycoside of isoflavone and β-D-glucan having anti-cancer effect and immunoenhancing effect, and a method of producing the glycoside from mushroom mycelium culture.
- In accordance with one aspect of the present invention, it is provided a method of producing isoflavone-β-D-glucan, which comprises the steps of:
- culturing Agaricus blazei mycelia in a liquid medium containing isoflavone to produce a high molecular weight isoflavone-β-D-glucan;
- separating the high molecular weight isoflavone-β-D-glucan from the liquid culture of Agaricus blazei mycelia;
- separating an autolysis enzyme from a separate liquid culture of Agaricus blazei mycelia;
- adding the autolysis enzyme to the high molecular weight isoflavone-β-D-glucan to produce a low and medium molecular weight isoflavone-β-D-glucan; and
- separating and purifying the low and medium molecular weight isoflavone-β-D-glucan.
- Preferably, the step of separating the high molecular weight isoflavone-β-D-glucan from the liquid culture of Agaricus blazei mycelia comprises:
- extracting the liquid culture of Agaricus blazei mycelia with boiling water and concentrating the extract;
- adding ethanol to the concentrated extract to make precipitation; and
- separating the precipitate.
- In the above step of separating the high molecular weight isoflavone-β-D-glucan from the liquid culture of Agaricus blazei mycelia, ethanol is preferably added in the concentration of 80%.
- Preferably, the step of separating an autolysis enzyme from a separate liquid culture of Agaricus blazei mycelia comprises:
- filtrating the liquid culture of Agaricus blazei mycelia under reduced pressure;
- adding trichloroacetic acid to the filtered liquid culture of Agaricus blazei mycelia to make precipitation; and
- separating the precipitate.
- In the above step of producing a low and medium molecular weight isoflavone-β-D-glucan, the autolysis enzyme is preferably added to the high molecular weight isoflavone-β-D-glucan at pH 4.5-5.5.
- In accordance with another aspect of the present invention, it is provided a method of producing isoflavone-β-D-glucan, which comprises the steps of:
- culturing Agaricus blazei mycelia in a liquid medium containing isoflavone to produce a high molecular weight isoflavone-β-D-glucan;
- activating an autolysis enzyme in the liquid culture of Agaricus blazei mycelia to produce a low and medium molecular weight isoflavone-β-D-glucan; and
- separating and purifying the low and medium molecular weight isoflavone-β-D-glucan.
- Preferably, the step of activating an autolysis enzyme from the liquid culture of Agaricus blazei mycelia is carried out by adjusting the pH of culture medium to pH 4.5-5.5 for 1-3 hours.
- In accordance with still another aspect of the present invention, it is provided a low and medium molecular weight isoflavone-β-D-glucan produced by the above-mentioned method.
- The low and medium molecular weight isoflavone-β-D-glucan produced from a liquid culture of Agaricus blazei mycelia is used as anti-cancer and immunoenhancing agent.
- Generally, polysaccharides having anti-cancer activity have been obtained from Basidiomycetes by extracting fruit body or mycelium cultured in solid medium or liquid medium. In solid culture, a long period of time is required for culturing and the process of extracting the anti-cancer polysaccharides is difficult. Further, the amount of polysaccharides extracted from fruit body is very low, and therefore, it is difficult to produce them on a large scale. On the other hand, in liquid culture, a short period of time is required, and it is possible to culture in a settled condition, which enables mycelia including a regular content of polysaccharides to be obtained on a large scale at low cost.
- The present invention is characterized in using Agaricus blazei mycelia as the mushroom mycelia cultured in liquid media containing isoflavone to produce low and medium molecular weight isoflavone-β-D-glucan.
- According to the present invention, low and medium molecular weight isoflavone-β-D-glucan is prepared from high molecular weight isoflavone-β-D-glucan extracted from liquid culture of Agaricus blazei mycelia, in order to enhance internal absorption thereof. In the present invention, autolysis enzyme secreted by Agaricus blazei mycelia is used to digest the high molecular weight isoflavone-β-D-glucan at an optimum condition for the activity of the enzyme. Especially, Agaricus blazei mycelium is selected for its highest activity of autolysis enzyme.
- Low and medium molecular weight isoflavone-β-D-glucan produced according to the present invention may be used for anti-cancer and immunoenhancing effect. The isoflavone-β-D-glucan of the present invention is very effective in killing cancer cells and shows no toxic effect on normal cells. It is found that isoflavone in free form has anti-cancer effect. However, the anti-cancer effect of isoflavone-β-D-glucan as glycoside has never been found before the present invention.
- Low and medium molecular weight isoflavone-β-D-glucan produced according to the present invention is characterized to have anti-cancer effect as well as immunoenhancing effect. The anti-cancer effect of the low and medium molecular weight isoflavone-β-D-glucan is remarkably increased with immunoenhancing effect.
- The above and other objects, features and other advantages of the present invention will be more clearly understood from the following detailed description taken in conjunction with the accompanying drawings, in which:
-
FIG. 1 shows a process of preparing a low and medium molecular weight isoflavone-β-D-glucan according to the present invention; -
FIG. 2 is HPLC chromatograms of the extract of liquid culture of Agaricus blazei mycelia treated with various concentrations of ethanol solution. -
FIG. 3 shows fractionation of the precipitate of the liquid culture of Agaricus blazei mycelia by DEAE column chromatography; -
FIG. 4 is UV spectrum of DEAE column fraction #2 (tube #8) at 225-445 nm; -
FIG. 5 shows SDS-PAGE pattern oftubes # 8 and #14; -
FIG. 6 shows TLC pattern of 80 EP reacted with autolysis enzyme; -
FIGS. 7 a and 7 b are HPLC chromatograms of each fraction containing autolysis enzyme separated from HPLC (TSK column) before and after being treated with 80 EP; -
FIG. 8 is HPLC chromatograms of the products from 80 EP treated withtube # 8, which are detected with UV detector and RI detector; -
FIG. 9 shows TLC pattern of soybean powder and its acid hydrolyzate; -
FIG. 10 is UV/VIS spectra of autolysis enzyme-treated 80 EP; -
FIGS. 11 a, 11 b and 11 c are IR spectra of TLC bands ofFIG. 9 ; -
FIG. 12 shows another process of preparing a low, and medium molecular weight isoflavone-β-D-glucan according to the present invention; -
FIG. 13 is a graph showing molecular weight of low and medium molecular weight isoflavone-β-D-glucan according to the present invention calculated by comparing with dextran standard and displayed in log scale; -
FIG. 14 is IR spectrum of low and medium molecular weight isoflavone-β-D-glucan according to the present invention; -
FIG. 15 is H-NMR spectrum of low and medium molecular weight isoflavone-β-D-glucan according to the present invention; -
FIG. 16 is UV spectrum of low and medium molecular weight isoflavone-β-D-glucan according to the present invention; -
FIG. 17 shows the composition of monosaccharide of low and medium molecular weight isoflavone-β-D-glucan according to the present invention; -
FIG. 18 shows the cytotoxic effects of the products of 80 EP treated with autolysis enzyme on human colon cancer Caco-2 cells; -
FIG. 19 shows the comparison of cytotoxicity of 80 EP treated withtube # 8 with various concentrations; and -
FIG. 20 shows the effect of 80 EP treated with autolysis enzyme on the reduction of ICR female mouse body weight induced by lipopolysaccharide (LPS). - Hereinafter, the present invention will be described in detail, in conjunction with various examples. These examples are provided only for illustrative purposes, and the present invention is not to be construed as being limited to these examples.
- First of all, a mushroom strain having highest activity of autolysis enzyme was selected. In an experiment for determining the activity of autolysis enzyme by measuring the change of viscosity in the liquid culture medium of Agaricus blazei (AB), Pleurotus ostreatus (PO), Coprinus comatus (CC), Lentinus edodes (LE), Phellinus linteus (PL) and Ganoderma lucidum (GL), Agaricus blazei (AB) was confirmed to have the highest activity.
-
FIG. 1 shows a process of preparing a low and medium molecular weight isoflavone-β-D-glucan according to the present invention. As shown inFIG. 1 , the process comprises step (1) of producing high molecular weight isoflavone-β-D-glucan by culturing AB mycelia in a liquid medium containing isoflavone. - In the next step (2), the high molecular weight isoflavone-β-D-glucan is separated from the liquid culture of AB mycelia by extracting the liquid culture with boiling water, concentrating the extract, adding ethanol to the concentrated extract to make precipitation and separating the precipitate. In the process of treating the extract with ethanol, 80% ethanol has the maximum effect on obtaining high molecular weight isoflavone-β-D-glucan.
- Further, the process of preparing a low and medium molecular weight isoflavone-β-D-glucan according to the present invention comprises step (3) of separating autolysis enzyme from a separate liquid culture of AB mycelia.
- The next process of preparing isoflavone-β-D-glucan is step (4) of adding the autolysis enzyme obtained from the liquid culture of AB mycelia to the high molecular weight isoflavone-β-D-glucan to produce a low and medium molecular weight isoflavone-β-D-glucan.
- The autolysis enzyme has the best activity in the condition of pH 4.5 to 5.5 and at the temperature of 53° C. for 1 to 3 hours. Considering the viscosity of product, the reaction for 3 hours appeared to be optimum. However, the effect of reaction time on producing low and medium molecular weight isoflavone-β-D-glucan had no difference between 3 hours and 1 hour. Accordingly, the reaction is preferable to be carried out for 1 hour.
- The process of preparing isoflavone-β-D-glucan according to the present invention further comprises step (5) of separating and purifying the low and medium molecular weight isoflavone-β-D-glucan. The low and medium molecular weight isoflavone-β-D-glucan is separated by DEAE column chromatography. The separated fraction is concentrated by vacuum concentrator and then separated by silica gel column chromatography.
-
FIG. 12 shows another process of preparing a low and medium molecular weight isoflavone-β-D-glucan according to the present invention. InFIG. 12 , 6 and 8 are carried out by the same procedure ofsteps 1 and 5 insteps FIG. 1 . However,step 7 inFIG. 12 are carried out by adjusting the pH of culture medium to 4.5-5.5 for 1-3 hours instead of treating the high molecular weight isoflavone-β-D-glucan with separated autolysis enzyme. - Agaricus blazei (AB), Pleurotus ostreatus (PO), Coprinus comatus (CC), Lentinus edodes (LE), Phellinus linteus (PL) and Ganoderma lucidum (GL) were cultured in liquid culture medium at 25° C. for three days in the condition of 1 v/v/m aeration. Liquid culture of each strain (10 ml) and polysaccharides prepared from the liquid culture were added with 80% ethanol (80 EP). The mixtures were then incubated at 53° C. and 63° C. for five hours. Degree of autolysis was determined by measuring the change of viscosity of 80 EP before and after the reaction. The following Table 1 shows the change of viscosity.
TABLE 1 Mushroom Viscosity (ml/sec) strains 0 hr After 5 hrs Δvis/hr AB 18,850 1,500 3,470 PO 1,250 650 120 CC 1,310 790 104 LE 1,120 970 30 PL 1,570 1,100 90 GL 1,750 1,210 108 - As shown in Table 1, AB has the highest value of 3,470 ml/sec in the change of viscosity (Δviscosity/hour). PO and CC also have rather higher values of 120 and 104 ml/sec. As a result, it is considered that AB has the highest degree of autolysis compared to other strains.
- The culture medium contained soybean powder or natural source including soybean powder. Natural isoflavone separated from soybean or synthetic isoflavone may also be used. The liquid medium were added with brown sugar as carbon source and inorganic salts, and then autoclaved at 120° C. for 30 minutes.
- AB mycelia were inoculated in the liquid culture medium containing isoflavone and cultured with aeration or stirring for 1 to 7 days to produce high molecular weight isoflavone-β-D-glucan. The molecular weight of the high molecular weight isoflavone-β-D-glucan was at least 30,000.
- Liquid culture of AB mycelia was extracted with boiling water at 100° C. for 10 hours, and the extract was autoclaved at 121° C. for 1 hour.
- The extract of liquid culture of AB mycelia was treated with 80% ethanol to make precipitation and then centrifuged to remove supernatant. The precipitate was separated to obtain high molecular weight isoflavone with β-D-glucan having the molecular weight of at least 100,000.
- The extract of liquid culture of AB mycelia was suspended in ethanol to prepare 10 to 80% ethanol solution to induce precipitation. Each precipitate was separated and then applied to Biosep S-2000 column.
-
FIG. 2 is HPLC chromatograms of the extract of liquid culture of Agaricus blazei mycelia treated with various concentrations of ethanol solution (40, 50, 60, 70 and 80% ethanol) and then separated with Biosep S-2000 column. The chromatogram on the right side below represents the chromatogram of total extract of liquid culture of AB mycelia. InFIG. 2 , horizontal axis represents time (minutes) and vertical axis represents length (mAU). - As shown in
FIG. 2 , the high molecular weight isoflavone-β-D-glucan, obtained by treating 80% ethanol to the liquid culture of AB mycelia to induce precipitation, hereinafter referred to ‘80 EP (80% ethanol precipitate)’, shows similar chromatograph pattern to 70 EP, both showing peaks at RT (retention time) 2.2 and 3. In 80 EP, the peak atRT 3 is higher than the peak at RT 2.2, while two peaks atRT 3 and 2.2 have similar heights to those of 70 EP. Other fractions have similar patterns to the total extract of liquid culture of AB mycelia, showing peaks at RT 2.2, 3 and 3.6. - From the above, it is considered that 80 EP has higher amount of high molecular weight isoflavone-β-D-glucan than other ethanol precipitates have. Further, 80 EP does not have unnecessary peaks, such as the peak at RT 3.6 which is found in other EP. Accordingly, 80 EP is used to increase the yield of isoflavone-β-D-glucan according to the present invention.
- The separation of autolysis enzyme was carried out by filtrating the liquid culture of AB mycelia at reduced pressure. TCA (trichloroacetic acid) was added to the filtrate to the concentration of 10% and the mixture was placed at 4° C. for 24 hours. The resultant was centrifuged at 4° C. and 10,000 rpm for 15 minutes to obtain the precipitate.
- The precipitate was further fractionated by DEAE (diethylaminoethyl) column chromatography and each fraction was determined its UV absorbance at 280 nm.
-
FIG. 3 shows fractionation of the precipitate of the liquid culture of Agaricus blazei mycelia by DEAE column chromatography. InFIG. 3 , horizontal axis represents number of each fraction and vertical axis represents UV absorbance at 280 nm. As shown inFIG. 3 , UV absorbance of each fraction was monitored and eight fractions were obtained showing UV absorbance at 280 nm. Fraction #2 (tube #8) showed the maximum UV absorbance. When autolysis activity of each fraction was tested,tube # 8 showed the highest activity. Accordingly,tube # 8 was used for treating the 80 EP obtained in Example 2 to prepare low and medium molecular weight isoflavone-β-D-glucan. -
FIG. 4 is UV spectrum of DEAE column fraction #2 (tube #8) at 225-445 nm. InFIG. 4 , horizontal axis represents wavelength, vertical axis represents absorbance, and the left box shows the numerical value of wavelength and absorbance. As shown inFIG. 4 , fraction #2 (tube #8) has the maximum UV absorbance at 270 nm. - The fraction of DEAE column chromatography was added to 80 EP obtained in Example 2. The production of low and medium molecular weight isoflavone-β-D-glucan from high molecular weight isoflavone-β-D-glucan was confirmed by using TSK column and C18 column. In TSK column chromatography, H2O was used as mobile phase at 1 ml/min. In C18 column chromatography, MeOH:1 mM ammonium acetate (6:4) was used as mobile phase at 1 min. Isoflavone was identified at UV 257 nm and 267 nm. RI detector was used to identify β-D-glucan.
- As
tube # 8 obtained in Example 3 showed maximum autolysis activity, molecular weight of the protein contained intube # 8 was determined by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis). - The fraction of
tube # 8 was dried and then SDS-PAGE sample buffer was added to dissolve the resultant. Electrophoresis was performed on 12% SDS-PAGE according to Laemmli. Size markers used were β-galactosidase (175 kDa), paramyosin (83 kDa), glutamic dehydrogenase (62 kDa), aldolase (48 kDa), triosephosphate isomerase (33 kDa), β-lactoglobulin A (25 kDa), lysozyme (17 kDa) and aprotinin (7 kDa) -
FIG. 5 shows SDS-PAGE pattern oftubes # 8 and #14. InFIG. 5 , SM of horizontal axis is size marker and vertical axis represents molecular weight of the protein used as size marker. As shown inFIG. 5 , molecular weight of the protein intube # 8 corresponds to 7 kDa, which shows that molecular weight of autolysis enzyme is about 7 kDa. - After adjusting its pH to 5.5, the high molecular weight isoflavone-β-D-glucan obtained by treating 80% ethanol to the liquid culture of AB mycelia (80 EP) was added with 10 ml of autolysis enzyme separated from DEAE column in Example 3. The mixture was placed at 53° C. for 1 hours to produce a low and medium molecular weight isoflavone-β-D-glucan. The molecular weight of obtained isoflavone-β-D-glucan was less than about 30,000.
- In order to determine the optimum condition for the activity of autolysis enzyme obtained from the liquid culture of AB mycelia, the liquid culture of AB mycelia and 80 EP were reacted at each conditions of pH 4.5, 5.5, 6.5 and 7.5 and temperature of 53° C. and 63° C. for 1, 3, 5, 15 and 24 hours and the viscosity was measured in each condition.
- Table 2 shows the viscosity of liquid culture of AB mycelia reacted with autolysis enzyme. As shown in Table 2, the autolysis enzyme obtained from AB mycelia has maximum activity at the condition of pH 4.5 to 5.5 and the temperature of 53° C. for 3 hours of reaction.
TABLE 2 53° C. 63° C. Reaction time pH 4.5 pH 5.5 pH 6.5 pH 7.5 pH 4.5 pH 5.5 pH 6.5 pH 7.5 0 18,750 18,850 19,300 19,750 18,750 18,850 19,300 19,750 1 hr 16,250 16,950 17,700 16,500 17,250 15,750 18,250 16,650 3 hrs 1,500 1,500 12,500 2,300 7,750 15,500 16,000 16,500 5 hrs 1,500 1,650 6,000 2,050 1,550 3,650 4,300 4,200 15 hrs 1,650 1,500 1,650 1,550 1,550 1,500 1,900 1,700 24 hrs 1,650 1,650 1,500 1,600 1,500 1,750 1,750 1,750 - As shown in Table 2, the viscosity of liquid culture of AB mycelia decreased from 18,750 to 1,500 after the reaction for 3 hours at the condition of pH 4.5 and 53° C. As a result, it is found that the autolysis enzyme has maximum activity at the condition of pH 4.5 to 5.5 and the temperature of 53° C. for 3 hours of reaction
- Low and medium molecular weight isoflavone-β-D-glucan was identified by TLC and HPLC.
- (1) Identification by TLC (Thin-Layer Chromatography)
- Free sugars or polymeric sugar has no UV absorbance. Therefore, in order to examine that an area separated by TLC has the material having UV absorbance, sugars, or sugars having UV absorbance, the separated band was detected with UV lamp and also analyzed by color development with diphenylamine aridine phosphate (DAP).
- The fraction separated by silica gel column chromatography was developed by TLC (Silica gel 60F-254 plate, 5×10 cm). The mobile phase was butanol:ethanol:H2O (5:3:3) (v/v/v). The separated band was treated by DAP and UV lamp was used to identify the material having UV absorbance.
-
FIG. 6 shows TLC pattern of 80 EP reacted with autolysis enzyme. In horizontal axis ofFIG. 6 , DP7 represents maltoheptose; DP4, maltotetrose; DP3, maltotriose; DT 5,000, dextran 5,000; DT 12,000, dextran 12000; DT 25,000, dextran 25,000; P+80% ethanol, 80 EP treated with autolysis enzyme; and 80% ethanol, 80 EP without treatment with autolysis enzyme. The vertical axis ofFIG. 6 represents Rf value which means the separation of material. - As shown in
FIG. 6 , low molecular weight polysaccharides (DP7 or less) move, while medium or higher molecular weight polysaccharides (MW 5,000) do not moved. In high molecular weight polysaccharides treated with autolysis enzyme, low molecular weight sugars (DP3 or less) showing color development by DAP are mixed with the materials having UV absorbance and showing color development by DAP. Especially, medium or higher molecular weight polysaccharides showing no movement have UV absorbance, and sugars of DP7 also have UV absorbance. Further, the materials having UV absorbance only are also included herein. - The above results show that high molecular weight polysaccharides are converted to medium and low molecular weight materials by autolysis and that the medium and low molecular weight materials are combined with the materials having UC absorbance.
- (2) Separation by HPLC (High Performance Liquid Chromatography)
- Bio-Sep S2000 column (mobile phase; 20 mM sodium phosphate), TSK column (mobile phase; H2O) and C18 column (mobile phase; MeOH:1 mM ammonium acetate (6:4)) were used. Flow rate was 1 ml/min in all cases. UV detector (UV 257 nm, 267 nm, 280 nm) and RI detector was used.
-
FIGS. 7 a and 7 b are HPLC chromatograms of each fraction containing autolysis enzyme separated from HPLC (TSK column) before and after treating with 80 EP. The horizontal axis represents time (minutes) and the vertical axis represents length (mAU). The left panel shows HPLC chromatograms of each fraction of #2, #8, #14, #25, #35, #65 and #83 treated with 80 EP a shows HPLC chromatograms of each fraction. - As shown in
FIGS. 7 a and 7 b, the uppermost chromatogram of 80 EP has four peaks. When each fraction of autolysis enzyme separated from DEAE chromatography (FIG. 3 ) was reacted with 80 EP, the fraction oftube # 8 showed different pattern from that of 80 EP, which represents that new product has been formed. In the other fractions, however, the original pattern of 80 EP was maintained, which means that digestion has not been carried out. Accordingly, it is considered that the high molecular polysaccharides contained in 80 EP have been digested into medium or low molecular weight polysaccharides by the reaction with the fraction oftube # 8. - Subsequently, the digest obtained from 80 EP treated with autolysis enzyme (tube #8) was separated with HPLC, and then monitored by UV detector and RI detector simultaneously.
-
FIG. 8 are HPLC chromatograms of the products from 80 EP treated withtube # 8, which are detected with UV detector and RI detector. InFIG. 8 , left panel A shows the result of RI detector and right panel B shows the result of UV detector (267 nm). As shown inFIG. 8 , only RT 8.8 peak is detected by both UV detector and RI detector, and the other peaks are detected either UV detector or RI detector. Considering the pattern of RT 8.8 peak, it is confirmed that polysaccharides are coupled with another material (having UV absorbance) which is considered to be isoflavone having UV absorbance. - In order to confirm that low and medium molecular weight isoflavone-β-D-glucan was produced by autolysis enzyme during the liquid culture of AB mycelia, TLC was carried out.
- When soybean powder (SP) was fractionated by ethanol (10, 20, 30, 40, 50, 60, 70 and 80%) and then each precipitate was separated, the most amount of precipitate was obtained in 70% ethanol, little amount was obtained in 10 to 60% ethanol, and small amount was obtained in 80% ethanol. Considering the most amount of precipitate derived from the liquid culture of AB mycelia has been obtained in 80 EP, it is considered that the precipitate contains such material that is not contained in SP but produced during the liquid culture of AB mycelia by bioconversion.
-
FIG. 9 shows TLC pattern of soybean powder (SP) and its acid hydrolyzate (SPH). InFIG. 9 , AP means precipitate of 80 EP obtained from the liquid culture of AB mycelia and then treated again with 80% ethanol; APH, acid-hydrolyzate of AP; AS, supernatant of the above 80 EP; ASH, hydrolyzate of AS; SP, soybean powder consisting of culture media; SPH, hydrolyzate of SP. G (genistein), D (daidzein) and GT (genistein standard) are markers and the vertical axis represents Rf values thereof. - As shown in
FIG. 9 , all the samples obtained from SP contain the materials having UV absorbance (RF 0.999, 0.542, 0.306) alone (especially, G and D, etc.) and do not contain the materials detected in UV lamp and DAP simultaneously, which shows that SP provides the materials having UV absorbance alone. On the other hand, the fraction obtained from AP has the material detected in UV and DAP simultaneously (Rf 0.542, 0.014), which means that the material is not contained in culture medium but produced during the liquid culture of AB mycelia by bioconversion. -
FIG. 10 is UV/VIS spectra of autolysis enzyme-treated 80 EP andFIGS. 11 a, 11 b and 11 c are IR spectra of TLC bands ofFIG. 9 . As shown inFIGS. 10, 11 a, 11 b and 11 c, all the spectra are similar to those of G and D, which means that they are glycosides of G or D. It is considered that the materials are produced during the liquid culture by bioconversion. - According to the above Examples 7 and 8, it is confirmed that high molecular weight β-D-glucan is digested to low and medium molecular weight β-D-glucan by autolysis enzyme, and the product is not made exclusively of low and medium molecular weight β-D-glucan but formed in combination with a certain material which is not polysaccharide.
- Isoflavone-β-D-glucan which is finally separated and purified according to the present invention (A) and isoflavone-β-D-glucan hydrolyzed by enzyme (β-glucosidase and megazyme kit) (B) were analyzed by HPLC (C18 column, mobile phase; MeOH: 1 mM ammonium acetate (6:4), flow rate; 1 ml/min).
- Table 3 shows the content of free genistein and daidzein in A and B.
TABLE 3 Genistein Daidzein isoflavone-β-D- — — glucan(A) isoflavone-β-D-glucan 150 mg/g dry weight 28.2 mg/g dry weight hydrolyzate (B) - As shown in Table 3, no free genistein and daidzein was detected in A and 150 mg/g dry weight of genistein and 28.2 mg/g dry weight of daidzein were detected in B. The result means that the final product of the present invention does not contain genistein and daidzein, free form of isoflavone, while the hydrolyzate of the final product contains them. Accordingly, it is considered that isoflavone is contained in the final product of the present invention (A), which contains isoflavone and β-D-glucan not as mixture but as glycoside.
- Molecular weight of low and medium molecular weight isoflavone-β-D-glucan was determined by HPLC equipped with TSK column (PDA-100 UV detector and RI detector, P-680 pump, ASI-100 fraction collector, Dionex). Mobile phase was triple distilled water and flow rate was 1 ml/min.
-
FIG. 13 is a graph showing molecular weight of low and medium molecular weight isoflavone-β-D-glucan according to the present invention calculated by comparing with dextran standard and displayed in log scale. As shown inFIG. 13 , molecular weight of low and medium molecular weight isoflavone-β-D-glucan was about 25,000. - Low and medium molecular weight isoflavone-β-D-glucan was separated again by HPLC (TSK column, mobile phase; H2O) and then a fraction showing the greatest anti-cancer effect was collected. In the fraction, sugar and isoflavone (genistein, daidzein) was determined by IR, H-NMR and UV spectra.
-
FIG. 14 is IR spectrum of low and medium molecular weight isoflavone-β-D-glucan according to the present invention. In IR spectrum, the characteristic peaks were 495-656 cm−1 (strong, broad), 1014 cm−1 (strong, narrow), 1109 cm−1 (weak, narrow), 1402.0, 1450.8, 1472.7 cm−1 (weak, broad), 1642.6 cm−1 (strong, narrow), 2097.0-2112.0 cm−1 (medium weak, broad), 2390 cm−1 (very weak, broad), 2843 cm−1 (medium, narrow in OH absorbance ˜3000 cm−1), 3173.0-3648 cm−1 (broad in OH absorbance ˜3000 cm−1), the characteristic peaks shown in IR spectrum of G or D standard. -
FIG. 15 is H-NMR spectrum andFIG. 16 is UV spectrum of low and medium molecular weight isoflavone-β-D-glucan according to the present invention. As shown inFIG. 15 , maximum absorbance was appeared in 267 nm, likewise that of G. Accordingly, it is considered that RT 8.8 peak indicates β-D-glucan containing mostly G among isoflavone. - Sample was added with 5 ml of phosphate buffer (20 mM, pH 6.5) and then digested by megazyme kit (β-glucosidase; 0.2 U, 0.1 ml) and licenase (10 U, 0.2 ml). The digest was analyzed by HPLC (Rezo RCM-monosaccharide column, 200×10 mm) to identify the composition of sugars.
-
FIG. 17 shows the composition of monosaccharide of low and medium molecular weight isoflavone-β-D-glucan according to the present invention (RT 8.8). As shown inFIG. 17 , the low and medium molecular weight isoflavone-β-D-glucan according to the present invention (RT 8.8) includes β-D-glucose, D-fructose and ribose. - 40 g of soybean or soybean powder was added with 10 g of protease and 10 g of cellulase and then digested at 60° C. and 200 rpm for 1 to 5 hours. The digest may be used with or without addition of 10 to 1000 mg of natural isoflavone separated from vegetables or synthetic isoflavone. 220 g of brown sugar, 3 g of ribose and inorganic salts (10 g of MgSO4, 10 g of KH2PO4) were added thereto and then water was added to make the total volume 1 l. The mixture was autoclaved at 121° C. for 1 hour to make liquid culture medium.
- Agaricus blazei mycelia were inoculated into the liquid medium, and then cultured upon shaking or aeration at 25-35° C. for 1-7 days.
- The culture obtained in Preparation Example 1 was autoclaved at 121° C. for 1 hour, filtrated through diatomite, and then concentrated to 1/10 volume under vacuum. 200 g of the concentrate was added with ethanol to be 80% ethanol solution and then mixed. The mixture was placed at 4° C. for 24 hours to induce precipitation. The precipitated liquid was centrifuged at 10,000 rpm for 10 minutes and the supernatant was removed to obtain 3.8 g of the precipitate containing β-D-glucan having the molecular weight of 100,000 or more (80 EP).
- Liquid culture of AB mycelia was filtrated under reduced pressure and the filtrate was mixed with TCA to make 10% TCA solution. The mixture was placed at 4° C. for 24 hours and then centrifuged at 4° C. and 10,000 rpm for 15 minutes to separate the precipitate.
- The precipitate was dissolved in 50 mM sodium acetate buffer (pH 5.0) and then separated by DEAE column (2 cm, 110 cm) to collect factions by 10 ml. The mobile phase was 20 mM sodium phosphate buffer (20 mM NaH2PO4 and 20 mM Na2HPO4, pH 7.0).
- After adjusting the pH to 5.5, 80 EP obtained in Preparation Example 2 was added with 10 ml of autolysis enzyme separated from DEAE column, and then the mixture was incubated in shaking incubator at 53° C. for 1 hour.
- The production of low and medium molecular weight isoflavone-β-D-glucan (MW 30,000 or less) by autolysis enzyme was confirmed by TLC and HPLC as mentioned above.
- (1) DEAE Column Chromatography
- 3 ml of the autolyzed product obtained in Preparation Example 4 was loaded on DEAE column (2 cm, 110 cm) filled with 5 mM sodium phosphate buffer (pH 7.7) and every 310 drops (10 ml) fractions were collected. The mobile phase was 5 mM sodium phosphate buffer (5 mM NaH2PO4 and 5 mM Na2HPO4, pH 7.7).
- (2) Silica Gel Column Chromatography
- The fraction obtained by DEAE column chromatography was concentrated by vacuum concentrator and separated again by silica gel column chromatography. The mobile phase was butanol:ethanol:H2O (5:3:3).
- Low and medium molecular weight isoflavone-β-D-glucan in the separated fraction was confirmed by TLC and HPLC as mentioned above.
- Hereinafter, the anti-cancer effect and immunoenhancing effect of low and medium molecular weight isoflavone-β-D-glucan as produced above will be described in detail, in conjunction with various examples.
- Experiment 1: Cytotoxicity Against S-180 Ascites Cancer Cells
- S-180 cells were maintained and subcultured at 37° C. in a humidified CO2 incubator (95% air-5% CO2). The complete medium for cell maintenance consisted of DMEM (Dulbecco's modified Eagle's medium) containing 10% horse serum, 100 U/ml penicillin and 100 μl/ml streptomycin. When cells were 80% confluent, the medium was changed every two days.
- 10 mg/ml of sample in double distilled water (DDW) was diluted by 10 fold in DMEM to make a sample solution containing 100 μl of DDW and 900 μl of DMEM, while control solution contained 100 μl of DDW and 900 μl of DMEM. 1.5×105 cells/ml of S-180 cells were diluted with DMEM to be 5×104 cells/ml of DMEM.
- To measure the effect of 80 EP on cell growth curves, cells were plated in complete medium in 24-well plates. All wells were treated with 5×104 cells/ml DMEM and then with each sample or control. The treated well plates were cultured in 5% CO2 incubator at 37° C. for 48 hours. Alive cells were dyed by 0.2% tryphane blue and the number of viable cells was determined by counting in a hemocytometer to calculate ED50.
- Table 4 shows the toxicity of the sample from 80 EP fraction treated with autolysis enzyme (tube #8) against S-180 cancer cells. As shown in Table 4, the cell number of control was 23.7×104 cells/ml after 48 hours of incubation. The cell numbers treated with autolyzed AB in each concentration of 10, 20 and 30 μg/ml were 7.5×104, 6.0×104 and 5.5×104 cells/ml, respectively, resulting in 0.9 μg/ml of ED50. On the other hand, the cell numbers treated with AB without autolysis in each concentration of 10, 20 and 30 μg/ml were 11.0×104, 9.5×104 and 8.5×104 cells/ml, respectively, resulting in 2.1 μg/ml of ED50. The result shows that the cytotoxicity increases in the sample treated with autolysis enzyme. Accordingly, it is considered that cytotoxic substances are generated from 80 EP fraction by the treatment of autolysis enzyme.
TABLE 4 Doses Growth of Cells Growth Ratio ED50 Treatment (μg/ml) (×104 cells/ml) (%) (μg/ml) Control 10 20 23.7 ± 2.5 100 — 30 AB 10 11.0 ± 0.7 31.11 20 9.5 ± 1.4 23.32 2.1 30 8.5 ± 0.7 18.14 Autolyzed 10 7.5 ± 0.7 12.95 AB 20 6.0 ± 0.1 5.18 0.9 30 5.5 ± 1.4 2.59 - Experiment 2: Anticarcinogenicity Against Mouse Ascite Cancer
- 7 week-old female ICR (Institute for Cancer Research) mice were obtained from Life Science (Taegu, Korea). S-180 cells were supplied by Korean Cell Line Bank (Seoul, Korea). The culture medium for S-180 was obtained by GIBCO and other reagents used were first grade.
- The ICR mice were grouped by 10 mice so that each group had equal mean body weight and then each group was put into a cage. The mice were raised freely with food and water for 1 week in an animal house at controlled room temperature and relative humidity. S-180 cells were subcultured as ascites type in ICR mice, and the tumor cells were harvested from the abdominal cavities of the
mice 7 days after the implantation. 0.1 ml of S-1 80 cells (1×107 cells/ml PBS) was transplanted subcutaneously into the abdomen of each mice to induce ascite cancer. 0.1 ml of test sample, dissolved or suspended in PBS (0.01M, pH 7.0) in adequate concentrations, was injected intraperitoneally every two days for 2 weeks, starting 24 hours after tumor implantation. After the intraperitoneal injection of S-180, the weight of mouse and the amount of feed intake were measured every three days for 40 days. The number of survived mice and the number of survival days were also measured. - Table 5 shows the number of survived mice and survival days of control group, the group treated with 80 EP, and the group treated with
autolyzed 80 EP. As shown in Table 5, the average survival days of control group was 19.2 days, while it was extended to 26.9 days (lengthen the life span by 40%) by the treatment of autolyzed AB and 3 mice were still alive after 40 days. The treatment of AB also lengthened survival days compared with control but less effective than autolyzed AB.TABLE 5 Treatment Mean survival days Survival rate (%) Survived mice Control 19.2 100 0/10 AB 22.3 116 0/10 Autolyzed AB 26.9 140 3/10 - Experiment 3: Cytotoxicity Against Human Cancer Cell Lines
- (1) Medium: 1 pack of DMEM was dissolved in 900 ml of triple distilled water and then added with 1 ml of penicillin-streptomycin. The mixture was added with 2 g of sodium bicarbonate and 100 ml of FBS (fetal bovine serum), and then filtrated by filter paper (0.22 μm). The complete medium for cell maintenance was stored at 4° C.
- (2) Cell culture: Human cancer cell lines (MCF-7, breast cancer and Hela, uterine cervix cancer cell) were subcultured in DMEM medium at 37° C. for 24 hours in 5% CO2 incubator. The cultured cell lines were treated with 1 ml of trypsin-EDTA at 37° C. for 10 minutes so that cells were separated from medium. Cells were recovered by centrifugation (1,500 rpm, 2 minutes) and then dissolved in the above medium. 1 ml of the medium containing cells was distributed in 12 well-plates so that each well contained 5×104 cells.
- (3) Cytotoxicity Against Hela Cell and MCF-7 Cell
- Table 6 shows the cytotoxicity of the samples from 80 EP fraction treated with or without autolysis enzyme (tube #8) against Hela cell (uterine cervix cancer cell line). As shown in Table 6, the cell number of Hela cells was 20.1×104 cells/ml after 48 hours incubation. ED50 values of AB and autolyzed AB were 5.6 and 0.9 μg/ml, respectively. Accordingly, it is considered that autolyzed AB has strong cytotoxicity and cytotoxic substances are produced from 80 EP fraction by the treatment of autolysis enzyme.
TABLE 6 Doses Growth of Cells Growth Ratio ED50 Treatment (μg/ml) (×104 cells/ml) (%) (μg/ml) Control 10 20 20.1 ± 1.1 100 — 30 AB 10 11.0 ± 1.4 36.4 20 9.5 ± 1.4 27.2 5.6 30 7.0 ± 0.7 12.1 Autolyzed 10 7.0 ± 0.7 18.1 AB 20 6.0 ± 0.1 15.1 0.9 30 5.5 ± 1.4 3.0 - Table 7 shows the cytotoxicity of the samples from 80 EP fraction treated with or without autolysis enzyme (tube #8) against MCF-7 cell (breast cancer cell line). As shown in Table 7, the cell number of MCF-7 cells was 21.5×104 cells/ml after 48 hours incubation. ED50 values of AB and autolyzed AB were 5.8 and 1.2 μg/ml, respectively, which were similar to those for Hela cells.
TABLE 7 Doses Growth of Cells Growth Ratio ED50 Treatment (μg/ml) (×104 cells/ml) (%) (μg/ml) Control 10 20 21.5 ± 2.1 100 — 30 AB 10 12.0 ± 1.4 39.3 20 9.5 ± 1.4 27.2 5.8 30 80 ± 1.4 18.1 Autolyzed 10 8.5 ± 0.7 21.2 AB 20 7.0 ± 0.1 18.1 1.2 30 5.5 ± 1.4 6.1 - (4) Cytotoxicity Against Caxo-2 Cells
- 80 EP fraction treated with autolysis enzyme (
tube # 8 or fractionated by HPLC asFIG. 5 ) was fractionated by DEAE cellulose column chromatography to collect 6 fractions (tube # 4, #14, #25, #32, #68 and #83). -
FIG. 18 shows the cytotoxic effects of the products of 80 EP treated with autolysis enzyme on human colon cancer Caco-2 cells. InFIG. 18 , the height of bar represents percentage of cell number after the treatment of autolysis enzyme as compared with control. As shown inFIG. 18 , 80 EP fraction without treatment of autolysis enzyme shows 85.7% of viability, that is, 14% of cytotoxicity. On the other hand,tube # 4 andtube # 14 treated with autolysis enzyme show 37% and 33% of cytotoxicity, respectively. Other samples also show toxicity at a lesser extent. These result also suggest that cytotoxic substances are produced from 80 EP fraction by the treatment of autolysis enzyme. -
FIG. 19 shows the comparison of cytotoxicity of 80 EP treated withtube # 8 with various concentrations. InFIG. 19 , sample A is 80 EP without treatment of autolysis enzyme and sample B is 80 EP treated with autolysis enzyme. The height of bar represents percentage of cell number after the treatment of autolysis enzyme as compared with control, in which concentration of white bar, dotted bar and shaded bar are 1, 5 and 10 mg, respectively. In sample A, cytotoxicity was not affected by the increase of concentration, while in sample B, cytotoxicity increased to 2, 23 and 42%, respectively, with the treatment of autolysis enzyme by 1, 5 and 10 mg. These result also suggests that cytotoxic substances are produced from 80 EP fraction by the treatment of autolysis enzyme. - Experiment 4: Immunoenhancing Effect of Isoflavone-β-D-glucan
- Female ICR mice (6-7 weeks of age) were housed in polycarbonated cage (4 mice/cage) and raised with feeding pellet fodder for mouse for 1 weeks and those of 28±1 g body weight were selected for experiment. All mice were raised freely with food and water in an animal house at 22±1° C. room temperature and 50% relative humidity maintaining light-and-dark cycle of 12 hour interval.
- One week later, the mice were subjected to one of the following treatments for 14 days: 0 (control), 1, 2 and 4 mg/g body weight/0.2 ml distilled water. Samples were injected per os. At the end of 14 consecutive feeding days, mice were weighted and injected intraperitoneally with 1 mg/kg body weight of lipopolysaccharide (LPS, Sigma Chemical Co.) in sterile HEPES buffer (Sigma Chemical Co.) or HEPES buffer alone. All mice were weighted 4, 8, 12, 24, 48 and 72 hours post injection.
-
FIG. 20 shows the effect of 80 EP treated with autolysis enzyme on the reduction of ICR female mouse body weight induced by lipopolysaccharide (LPD). InFIG. 20 , (1) represents control group; (2), (3) and (4) represent the groups treated with 1, 2 and 4 mg ofautolyzed 80 EP, respectively; and (5), (6) and (7) represent the groups treated with 1, 2 and 4 mg of 80 EP without treatment of autolysis enzyme. - LPS, a complex of lipid and polysaccharide with a covalent bond, forms an endotoxin consisting in outer membrane component of Gram negative bacteria. LPS has various biological activity and is called endotoxin. LPS of bacteria is recognized as the signal of infection by the immune system of host. Accordingly, immune ability may be presumed by determining the reduction of body weight after the treatment of LPS.
- As shown in
FIG. 20 , all mice treated with LPS showed reduction of body weight. In control mice treated with LPS, body weight decreased dramatically with the lapse of time and resulted in 2.42 g reduction in 24 hours after the treatment of LPS. The treatment of 80 EP treated with autolysis enzyme (autolyzed AB) suppressed the reduction of body weight as compared with that of control. In autolyzed AB groups, the reductions of body weight in 24 hours after the treatment of LPS were −1.77, −1.22 and −0.75 g, respectively, with the treatment of 1, 2 and 4 mg of autolyzed AB. Accordingly, it is considered that autolyzed AB may reduce the effect of LPS. The AB sample (80 EP without treatment of autolyzed enzyme) was less effective for the suppression of body weight reduction, compared to autolyzed AB sample. These results suggest that active substances which may suppress the effect of LPS in ICR mice are produced from 80 EP fraction by the treatment of autolysis enzyme, which means low and medium molecular weight isoflavone-β-D-glucan has immunoenhancing effect. - The present invention provides low and medium molecular weight isoflavone-β-D-glucan produced by submerged liquid culture of Agaricus blazei, a method of producing the isoflavone-β-D-glucan using autolysis enzyme of Agaricus blazei mycelia, and use of the isoflavone-β-D-glucan for anti-cancer and immunoenhancing effect.
- According to the present invention, low and medium molecular weight isoflavone-β-D-glucan is prepared from high molecular weight isoflavone-β-D-glucan extracted from liquid culture of Agaricus blazei mycelia, by using autolysis enzyme secreted by Agaricus blazei mycelia at an optimum condition for the activity of the enzyme. The process requires a short period of time and enables the product to be obtained on a large scale at low cost.
- Low and medium molecular weight isoflavone-β-D-glucan of the present invention has anti-cancer effect as well as immunoenhancing effect without toxic effect on normal cells. The anti-cancer effect is remarkably increased with immunoenhancing effect.
Claims (4)
1. A method of producing isoflavone-β-D-glucan, which comprises the steps of:
culturing Agaricus blazei mycelia in a liquid medium containing isoflavone to produce a high molecular weight isoflavone-β-D-glucan;
activating an autolysis enzyme in the liquid culture of Agaricus blazei mycelia to produce a low and medium molecular weight isoflavone-β-D-glucan; and
separating and purifying the low and medium molecular weight isoflavone-β-D-glucan.
2. The method according to claim 1 , wherein the step of activating an autolysis enzyme from the liquid culture of Agaricus blazei mycelia is carried out by adjusting the pH of culture medium to pH 4.5-5.5 for 1-3 hours.
3. The isoflavone-β-D-glucan produced by the method of claim 1 .
4. An immunoenhancing agent comprising the isoflavone-β-D-glucan of claim 3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/282,901 US20060078971A1 (en) | 2003-09-29 | 2005-11-18 | Isoflavone-beta-D-glucan produced by Agaricus blazei in the submerged liquid culture and method of producing same |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2003-0067439A KR100491186B1 (en) | 2003-09-29 | 2003-09-29 | THE ISOFLAVONE-β-D-GLUCAN PRODUCED BY AGARICUS BLAZEI IN THE SUBMERGED LIQUID CULTUR AND THE PRODUCING METHOD THERE OF |
| KR2003-0067439 | 2003-09-29 | ||
| US10/890,537 US7060470B2 (en) | 2003-09-29 | 2004-07-12 | Isoflavone-β-D-glucan produced by Agaricus blazei in the submerged liquid culture and method of producing same |
| US11/282,901 US20060078971A1 (en) | 2003-09-29 | 2005-11-18 | Isoflavone-beta-D-glucan produced by Agaricus blazei in the submerged liquid culture and method of producing same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/890,537 Division US7060470B2 (en) | 2003-09-29 | 2004-07-12 | Isoflavone-β-D-glucan produced by Agaricus blazei in the submerged liquid culture and method of producing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20060078971A1 true US20060078971A1 (en) | 2006-04-13 |
Family
ID=36145844
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/890,537 Expired - Lifetime US7060470B2 (en) | 2003-09-29 | 2004-07-12 | Isoflavone-β-D-glucan produced by Agaricus blazei in the submerged liquid culture and method of producing same |
| US11/282,901 Abandoned US20060078971A1 (en) | 2003-09-29 | 2005-11-18 | Isoflavone-beta-D-glucan produced by Agaricus blazei in the submerged liquid culture and method of producing same |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/890,537 Expired - Lifetime US7060470B2 (en) | 2003-09-29 | 2004-07-12 | Isoflavone-β-D-glucan produced by Agaricus blazei in the submerged liquid culture and method of producing same |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US7060470B2 (en) |
| JP (1) | JP4090438B2 (en) |
| KR (1) | KR100491186B1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100491186B1 (en) * | 2003-09-29 | 2005-05-25 | (주)에이치케이바이오텍 | THE ISOFLAVONE-β-D-GLUCAN PRODUCED BY AGARICUS BLAZEI IN THE SUBMERGED LIQUID CULTUR AND THE PRODUCING METHOD THERE OF |
| US7514085B2 (en) * | 2004-07-16 | 2009-04-07 | Medimush A/S | Immune modulating compounds from fungi |
| CA2607004C (en) | 2005-05-05 | 2016-01-26 | Sensient Flavors Inc. | Production of beta-glucans and mannans |
| WO2006119774A1 (en) * | 2005-05-13 | 2006-11-16 | Medimush As | Feed or food products comprising fungal material |
| WO2006133707A2 (en) * | 2005-06-15 | 2006-12-21 | Medimush A/S | Anti-cancer combination treatment and kit-of-part |
| US20090005340A1 (en) * | 2005-06-15 | 2009-01-01 | Medimush A/S | Bioactive Agents Produced By Submerged Cultivation of a Basidiomycete Cell |
| KR101633610B1 (en) * | 2011-12-14 | 2016-06-28 | 일동제약주식회사 | Microencapsulation of spore-forming probiotics removed an autolysin and spore-forming probiotics prepared thereby |
| JP6353225B2 (en) * | 2013-12-27 | 2018-07-04 | 焼津水産化学工業株式会社 | Process for producing β-glucan-containing composition from basidiomycetes |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7060470B2 (en) * | 2003-09-29 | 2006-06-13 | Hk Biotech Co., Ltd. | Isoflavone-β-D-glucan produced by Agaricus blazei in the submerged liquid culture and method of producing same |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6897046B2 (en) * | 1997-04-08 | 2005-05-24 | Japan Applied Microbiology Research Institute Ltd. | Process of preparing biologically active substance |
-
2003
- 2003-09-29 KR KR10-2003-0067439A patent/KR100491186B1/en not_active Expired - Fee Related
-
2004
- 2004-02-16 JP JP2004038950A patent/JP4090438B2/en not_active Expired - Lifetime
- 2004-07-12 US US10/890,537 patent/US7060470B2/en not_active Expired - Lifetime
-
2005
- 2005-11-18 US US11/282,901 patent/US20060078971A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7060470B2 (en) * | 2003-09-29 | 2006-06-13 | Hk Biotech Co., Ltd. | Isoflavone-β-D-glucan produced by Agaricus blazei in the submerged liquid culture and method of producing same |
Also Published As
| Publication number | Publication date |
|---|---|
| US7060470B2 (en) | 2006-06-13 |
| JP4090438B2 (en) | 2008-05-28 |
| KR20050031212A (en) | 2005-04-06 |
| US20050069989A1 (en) | 2005-03-31 |
| KR100491186B1 (en) | 2005-05-25 |
| JP2005105247A (en) | 2005-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6383799B1 (en) | Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher basidiomycetes mushroom | |
| FI110324B (en) | New polysaccharides and their preparation | |
| Reshetnikov et al. | Medicinal value of the genus Tremella Pers.(Heterobasidiomycetes) | |
| JP2003520576A (en) | Method, method and composition for producing cholesterol-lowering agent from higher basidiomycetes mushroom | |
| Zhuang et al. | Antitumor Activity and Immunological Property of Polysaccharides from the Mycelium of LiquidCultured Grifota frondosa | |
| US7060470B2 (en) | Isoflavone-β-D-glucan produced by Agaricus blazei in the submerged liquid culture and method of producing same | |
| AU2006273203B2 (en) | Strain of turkey tail mushroom, extract from the same, and use of the same | |
| JP4032372B2 (en) | Anticancer substance | |
| KR100340663B1 (en) | A method of preparing the antitumor and immuno-activity polysaccharide from the artificial cultivation of inonotus obliquus, and its use | |
| Sułkowska-Ziaja et al. | Biologically active compounds of fungal origin displaying antitumor activity | |
| Choi et al. | Enhancement of anti-complementary and radical scavenging activities in the submerged culture of Cordyceps sinensis by addition of citrus peel | |
| JPH11228441A (en) | Biological antioxidant function enhancer | |
| JP2004329077A (en) | CULTURE PRODUCT, NEW beta-1,3-1,6 GLUCAN CONTAINED IN THE SAME AND METHOD FOR PRODUCING beta-1,3-1.6 GLUCAN USING STRAIN OF GENUS AUREOBASIDIUM | |
| KR100706132B1 (en) | Media composition for culturing Felinus linteus mycelium | |
| KR100265319B1 (en) | Novel AGARICUSBLAZEI IY709 Strains and Pharmacologically Active Polysaccharide Fractions Isolated therefrom | |
| WO2002062813A1 (en) | Novel substance having physiological activity, process for producing the same, and use | |
| KR100320743B1 (en) | Extracts of Phellinus linteus having anti-oxidizing, whitening, moisturizing, immunoenhancing and anti-acne activities, preparation method and use thereof | |
| CN1425693A (en) | Water soluble heteropolysaccharide and its preparing method and use | |
| KR100729213B1 (en) | Extracellular Biopolymers Isolated from Liquid Cultures of Leafy Mushrooms with Immune Enhancing Activity | |
| CN114540202B (en) | Preparation method of sparassis crispa dry powder, physiological function active agent and application thereof | |
| KR0143512B1 (en) | Immunopotentive agents and isolating methods from cultivated ganoderma lucidum | |
| KR101170979B1 (en) | Method of obtaining a glucoside and glucoside using the same | |
| Mizuno et al. | Ningyotake, Polyporus confluens: Biologically active substances | |
| JPH07277971A (en) | Antitumor agent, selective cytotoxic agent for human tumor cell, microbial strain producing heptelidic acid chlorohydrin and its production | |
| BRPI1003147A2 (en) | mycelium and bioactive mushroom production process in co-cultivation by submerged fermentation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |